Without using animals: antibodies from algae for pregnancy tests

Start-up develops new process - DBU provides funding

19-Nov-2024 - It is not every day that young start-ups from Germany launch an innovation with industry-changing potential onto the market. But this is exactly what Phaeosynt, a company founded out of the University of Hanover, is planning to do with its diatom-derived antibodies for medical diagnostics. Until ...

Biointron Insights: Antibody Industry Report

04-Nov-2024 - This report aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September). Besides PiaSky, Vyloy, Imdelltra, Tribuvia, and ivonescimab, five more novel antibody drugs have been approved this year: Enlonstobart (Enshuxing), Donanemab (Kisunla), ...

Generative AI antibody design platform

Antiverse raises £3.5M

21-Oct-2024 - Antiverse, a techbio company designing antibodies for challenging targets, announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many ...

YUMAB cooperates with AI specialist

YUMAB and MOLCURE collaborate to advance zero-shot AI antibody discovery technology for undruggable targets

17-Oct-2024 - YUMAB GmbH, a antibody discovery CRO headquartered in Braunschweig, Germany, and MOLCURE Inc., an AI-driven drug discovery company based in Kawasaki, Japan, announced their on-going collaboration now includes advancing the application of zero-shot AI technology for antibody discovery. The ...

Impressive results against autoimmune disease

Severe systemic lupus no longer detectable after cancer medication treatment

06-Sep-2024 - The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune ...

Autoantibodies Cause Lifelong Risk of Viral Infections

19-Jul-2024 - A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life. This makes individuals more susceptible to viral diseases like COVID-19. The study, conducted by UZH researchers together with a USZ team, is based on an analysis of ...

Novel anti-cancer therapy: Prevention or reversal of cancer resistance

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

18-Jul-2024 - CatalYm announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, ...

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

Novel and potentially groundbreaking therapeutic strategy

10-Jul-2024 - SciRhom GmbH announced the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including ...

New antibody harbours great potential for fighting blood cancer

Already tested antibody also shows promise for ALL

03-Jul-2024 - Kiel cancer researchers from Kiel University and UKSH are testing an antibody clinically proven in autoimmune diseases for the treatment of childhood leukaemia and can demonstrate good efficacy against cancer cells in model trials. Acute lymphoblastic leukaemia (ALL) is the most common cancer in ...

Lab-Made Sugars and Nanobodies from Alpacas Against Cancer: Oren Moscovitz Wins Prestigious Hermann Neuhaus Prize

Two start-ups are already working to bring these findings closer to public fruition

18-Jun-2024 - Dr. Oren Moscovitz has been awarded €25,000 by the Max Planck Society for his promising research toward treatments and non-invasive diagnostics for cancer, which could potentially reduce overall cancer-related deaths. Moscovitz and his team exploit unique sugar patterns found on cancer cells and ...